JP2016519147A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519147A5 JP2016519147A5 JP2016514126A JP2016514126A JP2016519147A5 JP 2016519147 A5 JP2016519147 A5 JP 2016519147A5 JP 2016514126 A JP2016514126 A JP 2016514126A JP 2016514126 A JP2016514126 A JP 2016514126A JP 2016519147 A5 JP2016519147 A5 JP 2016519147A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound
- bipyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 68
- 150000003839 salts Chemical class 0.000 claims 54
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 53
- 150000001875 compounds Chemical class 0.000 claims 50
- -1 H 2 N— Chemical group 0.000 claims 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims 28
- 125000001424 substituent group Chemical group 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 10
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 10
- 125000001309 chloro group Chemical group Cl* 0.000 claims 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 206010028537 myelofibrosis Diseases 0.000 claims 7
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 6
- 208000003476 primary myelofibrosis Diseases 0.000 claims 6
- MSGYSFWCPOBHEV-AWEZNQCLSA-N 4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1h-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-n-[(2s)-1,1,1-trifluoropropan-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)N[C@@H](C)C(F)(F)F)=CC(F)=C1N1CC(CC#N)(N2N=CC(=C2)C2=C(NN=C2C)C)C1 MSGYSFWCPOBHEV-AWEZNQCLSA-N 0.000 claims 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000006601 (C1-C3) alkylcarbamyl group Chemical group 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 3
- 208000009527 Refractory anemia Diseases 0.000 claims 3
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 3
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 3
- 208000037244 polycythemia vera Diseases 0.000 claims 3
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 206010033661 Pancytopenia Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 208000024389 cytopenia Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims 1
- IADHQAYOJSDLQB-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-(5-methyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-propan-2-ylbenzamide Chemical compound CC(C)NC(=O)c1ccc(cc1)N1CC(CC#N)(C1)n1cc(cn1)-c1c[nH]nc1C IADHQAYOJSDLQB-UHFFFAOYSA-N 0.000 claims 1
- WDEZBQCRCIAJPW-UHFFFAOYSA-N 5-[3-(cyanomethyl)-3-[3-methyl-4-(1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-propan-2-ylpyrazine-2-carboxamide Chemical compound CC(C)NC(=O)c1cnc(cn1)N1CC(CC#N)(C1)n1cc(c(C)n1)-c1cn[nH]c1 WDEZBQCRCIAJPW-UHFFFAOYSA-N 0.000 claims 1
- UVNZXZQWOUVYIS-UHFFFAOYSA-N 5-[3-(cyanomethyl)-3-[3-methyl-4-(5-methyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-propan-2-ylpyrazine-2-carboxamide Chemical compound CC(C)NC(=O)c1cnc(cn1)N1CC(CC#N)(C1)n1cc(c(C)n1)-c1c[nH]nc1C UVNZXZQWOUVYIS-UHFFFAOYSA-N 0.000 claims 1
- JFFRGYYXQJTLOG-UHFFFAOYSA-N 5-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-propan-2-ylpyrazine-2-carboxamide Chemical compound CC(C)NC(=O)c1cnc(cn1)N1CC(CC#N)(C1)n1cc(cn1)-c1c(C)n[nH]c1C JFFRGYYXQJTLOG-UHFFFAOYSA-N 0.000 claims 1
- ZNDIFOVCUNVGNF-UHFFFAOYSA-N 5-[3-(cyanomethyl)-3-[4-(5-methyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-propan-2-ylpyrazine-2-carboxamide Chemical compound CC(C)NC(=O)c1cnc(cn1)N1CC(CC#N)(C1)n1cc(cn1)-c1c[nH]nc1C ZNDIFOVCUNVGNF-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 claims 1
- 208000031404 Chromosome Aberrations Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 101100095974 Mus musculus Smc3 gene Proteins 0.000 claims 1
- AYNNRIXQAVTECA-ZETCQYMHSA-N N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide Chemical compound C(C1=CC=CC=C1)(=O)N[C@H](C(F)(F)F)C AYNNRIXQAVTECA-ZETCQYMHSA-N 0.000 claims 1
- BISZGLXXDZHLIN-FJXQXJEOSA-N P(O)(O)(O)=O.C(C1=CC=CC=C1)(=O)N[C@H](C(F)(F)F)C Chemical compound P(O)(O)(O)=O.C(C1=CC=CC=C1)(=O)N[C@H](C(F)(F)F)C BISZGLXXDZHLIN-FJXQXJEOSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- 206010070835 Skin sensitisation Diseases 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- 208000005485 Thrombocytosis Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- DDAMPNWYDILDPV-UHFFFAOYSA-N benzamide;phosphoric acid Chemical compound OP(O)(O)=O.NC(=O)C1=CC=CC=C1 DDAMPNWYDILDPV-UHFFFAOYSA-N 0.000 claims 1
- HLWOEQNDJYGYJV-UHFFFAOYSA-N benzamide;sulfuric acid Chemical compound OS(O)(=O)=O.NC(=O)C1=CC=CC=C1 HLWOEQNDJYGYJV-UHFFFAOYSA-N 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 231100000046 skin rash Toxicity 0.000 claims 1
- 231100000370 skin sensitisation Toxicity 0.000 claims 1
- 208000009996 subepithelial mucinous corneal dystrophy Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361824683P | 2013-05-17 | 2013-05-17 | |
| US61/824,683 | 2013-05-17 | ||
| PCT/US2014/038388 WO2014186706A1 (en) | 2013-05-17 | 2014-05-16 | Bipyrazole derivatives as jak inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018187613A Division JP6775560B2 (ja) | 2013-05-17 | 2018-10-02 | Ｊａｋ阻害剤としてのビピラゾール誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519147A JP2016519147A (ja) | 2016-06-30 |
| JP2016519147A5 true JP2016519147A5 (https=) | 2017-06-29 |
| JP6415543B2 JP6415543B2 (ja) | 2018-10-31 |
Family
ID=50983151
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514126A Active JP6415543B2 (ja) | 2013-05-17 | 2014-05-16 | Ｊａｋ阻害剤としてのビピラゾール誘導体 |
| JP2018187613A Active JP6775560B2 (ja) | 2013-05-17 | 2018-10-02 | Ｊａｋ阻害剤としてのビピラゾール誘導体 |
| JP2020168950A Active JP7126741B2 (ja) | 2013-05-17 | 2020-10-06 | Ｊａｋ阻害剤としてのビピラゾール誘導体 |
| JP2022128042A Pending JP2022163162A (ja) | 2013-05-17 | 2022-08-10 | Ｊａｋ阻害剤としてのビピラゾール誘導体 |
| JP2024079435A Pending JP2024105557A (ja) | 2013-05-17 | 2024-05-15 | Ｊａｋ阻害剤としてのビピラゾール誘導体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018187613A Active JP6775560B2 (ja) | 2013-05-17 | 2018-10-02 | Ｊａｋ阻害剤としてのビピラゾール誘導体 |
| JP2020168950A Active JP7126741B2 (ja) | 2013-05-17 | 2020-10-06 | Ｊａｋ阻害剤としてのビピラゾール誘導体 |
| JP2022128042A Pending JP2022163162A (ja) | 2013-05-17 | 2022-08-10 | Ｊａｋ阻害剤としてのビピラゾール誘導体 |
| JP2024079435A Pending JP2024105557A (ja) | 2013-05-17 | 2024-05-15 | Ｊａｋ阻害剤としてのビピラゾール誘導体 |
Country Status (36)
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 |
| CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| PT3354652T (pt) | 2010-03-10 | 2020-07-20 | Incyte Holdings Corp | Derivados de piperidin-4-ilazetidina como inibidores de jak1 |
| RS54824B1 (sr) | 2010-05-21 | 2016-10-31 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| KR102507287B1 (ko) | 2011-09-02 | 2023-03-07 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
| CN113384546A (zh) | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
| WO2014138168A1 (en) | 2013-03-06 | 2014-09-12 | Incyte Corporation | Processes and intermediates for making a jak inhibitor |
| SMT201900223T1 (it) * | 2013-05-17 | 2019-07-11 | Incyte Corp | Sale di bipirazolo come inibitore di jak |
| SG10201801069QA (en) | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| JP6576941B2 (ja) * | 2014-02-28 | 2019-09-18 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | 骨髄異形成症候群の治療のためのｊａｋ１阻害剤 |
| PH12020552277A1 (en) | 2014-04-08 | 2023-07-17 | Incyte Holdings Corp | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| HK1248570A1 (zh) * | 2015-05-29 | 2018-10-19 | 西德奈克西斯公司 | D2o稳定化的药物制剂 |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| WO2017120194A1 (en) | 2016-01-05 | 2017-07-13 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| CN107759623B (zh) * | 2016-08-23 | 2020-08-14 | 苏州旺山旺水生物医药有限公司 | Jak抑制剂的中间体及其制备方法 |
| CN109890817B (zh) * | 2016-09-06 | 2022-06-17 | 豪夫迈·罗氏有限公司 | 8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法 |
| KR20240152947A (ko) | 2017-10-18 | 2024-10-22 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| EA202091830A1 (ru) | 2018-01-30 | 2020-12-29 | Инсайт Корпорейшн | Способы и промежуточные соединения для получения ингибитора jak |
| IL311485B1 (en) | 2018-02-16 | 2026-01-01 | Incyte Corp | JAK1 pathway inhibitors for the treatment of cytokine-related disorders |
| MD3773593T2 (ro) | 2018-03-30 | 2024-10-31 | Incyte Corp | Tratament hidradenitei supurative utilizând inhibitori ai JAK |
| WO2019191679A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| CA3097025A1 (en) | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| CN108484468A (zh) * | 2018-05-11 | 2018-09-04 | 南京大学 | 芳基氮杂环丁烷类化合物的制备方法 |
| CA3101323A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| CA3123596A1 (en) | 2018-12-19 | 2020-06-25 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
| MA55201A (fr) | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| EP4041204A1 (en) | 2019-10-10 | 2022-08-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| WO2021076124A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| FI4157831T3 (fi) * | 2020-06-02 | 2024-12-02 | Incyte Corp | Menetelmiä jak1-estäjän valmistamiseksi |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CR20230130A (es) | 2020-08-18 | 2023-07-13 | Incyte Corp | Proceso e intermedios para preparar un inhibidor de jak1 |
| CA3192099A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak inhibitor |
| CN112159394B (zh) * | 2020-10-09 | 2021-10-22 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的小分子化合物及其用途 |
| US12005067B2 (en) | 2020-12-04 | 2024-06-11 | Incyte Corporation | JAK inhibitor with a vitamin D analog for treatment of skin diseases |
| WO2022125670A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
| TW202241439A (zh) * | 2020-12-29 | 2022-11-01 | 大陸商上海岸闊醫藥科技有限公司 | 治療與抗腫瘤劑相關的皮膚疾病或病症的試劑和方法 |
| CN114081889A (zh) * | 2020-12-29 | 2022-02-25 | 上海岸阔医药科技有限公司 | 预防或治疗egfr功能异常相关的副作用的方法 |
| EP4274578A1 (en) | 2021-01-11 | 2023-11-15 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
| RS67455B1 (sr) | 2021-05-03 | 2025-12-31 | Incyte Corp | Inhibitori jak1 puta za lečenje prurigo nodularisa |
| CN118317946A (zh) | 2021-07-12 | 2024-07-09 | 因赛特公司 | 用于制备巴瑞替尼的方法和中间体 |
| IL318652A (en) | 2022-08-05 | 2025-03-01 | Incyte Corp | Treatment of urticaria with JAK inhibitors |
| TW202438061A (zh) | 2023-03-16 | 2024-10-01 | 美商英塞特公司 | 用於治療氣喘之ｊａｋ１路徑抑制劑 |
| CN117186078A (zh) * | 2023-11-06 | 2023-12-08 | 药康众拓(北京)医药科技有限公司 | 氘代氮杂环丁烷类jak抑制剂药物及用途 |
| WO2025226637A1 (en) | 2024-04-22 | 2025-10-30 | Incyte Corporation | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60106847U (ja) | 1983-12-27 | 1985-07-20 | 富士重工業株式会社 | 室外後写鏡 |
| JP2650681B2 (ja) | 1987-07-10 | 1997-09-03 | 株式会社ブリヂストン | 空気ばね |
| JPH0515775Y2 (https=) | 1987-07-13 | 1993-04-26 | ||
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| ATE273695T1 (de) | 2000-06-28 | 2004-09-15 | Smithkline Beecham Plc | Nassvermahlung |
| IL160915A0 (en) | 2001-09-19 | 2004-08-31 | Aventis Pharma Sa | Indolizines inhibiting kinase proteins |
| ES2269793T3 (es) | 2001-10-30 | 2007-04-01 | Novartis Ag | Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3. |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| RU2007123675A (ru) | 2004-11-24 | 2008-12-27 | Новартис АГ (CH) | Комбинации ингибиторов jak |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| WO2009064835A1 (en) * | 2007-11-16 | 2009-05-22 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| CA3121743A1 (en) | 2009-01-15 | 2010-07-22 | Incyte Holdings Corporation | Processes for preparing jak inhibitors and related intermediate compounds |
| JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 |
| SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| KR101921850B1 (ko) | 2009-10-09 | 2018-11-23 | 인사이트 홀딩스 코포레이션 | 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체 |
| EP2536729A1 (en) | 2010-02-18 | 2012-12-26 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
| PT3354652T (pt) | 2010-03-10 | 2020-07-20 | Incyte Holdings Corp | Derivados de piperidin-4-ilazetidina como inibidores de jak1 |
| KR20130094710A (ko) * | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 |
| RS54824B1 (sr) | 2010-05-21 | 2016-10-31 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
| CA2818542A1 (en) * | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| WO2012076063A1 (en) * | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| EP2678686B1 (en) | 2011-02-24 | 2017-10-11 | Massachusetts Institute of Technology | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013041042A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Pyrazole carboxamides as janus kinase inhibitors |
| TW201406761A (zh) * | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
| CN113384546A (zh) | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
| WO2014138168A1 (en) | 2013-03-06 | 2014-09-12 | Incyte Corporation | Processes and intermediates for making a jak inhibitor |
| SMT201900223T1 (it) | 2013-05-17 | 2019-07-11 | Incyte Corp | Sale di bipirazolo come inibitore di jak |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| TWI651300B (zh) | 2013-05-17 | 2019-02-21 | 健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| CN105209470B (zh) | 2013-05-17 | 2018-02-06 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的6‑桥连的杂芳基二氢嘧啶 |
| SG10201801069QA (en) | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| JP6576941B2 (ja) | 2014-02-28 | 2019-09-18 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | 骨髄異形成症候群の治療のためのｊａｋ１阻害剤 |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| HRP20192009T1 (hr) | 2014-12-16 | 2020-02-07 | Novartis Ag | Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a |
| IL311485B1 (en) | 2018-02-16 | 2026-01-01 | Incyte Corp | JAK1 pathway inhibitors for the treatment of cytokine-related disorders |
| FI4157831T3 (fi) | 2020-06-02 | 2024-12-02 | Incyte Corp | Menetelmiä jak1-estäjän valmistamiseksi |
| US12005067B2 (en) | 2020-12-04 | 2024-06-11 | Incyte Corporation | JAK inhibitor with a vitamin D analog for treatment of skin diseases |
| WO2022125670A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
-
2014
- 2014-05-16 SM SM20190223T patent/SMT201900223T1/it unknown
- 2014-05-16 DK DK18215671.1T patent/DK3527263T3/da active
- 2014-05-16 MX MX2015015738A patent/MX373238B/es active IP Right Grant
- 2014-05-16 LT LTEP20201593.9T patent/LT3786162T/lt unknown
- 2014-05-16 RS RS20230782A patent/RS64591B1/sr unknown
- 2014-05-16 ES ES17158350T patent/ES2720073T3/es active Active
- 2014-05-16 HR HRP20170795TT patent/HRP20170795T1/hr unknown
- 2014-05-16 RS RS20190315A patent/RS58743B1/sr unknown
- 2014-05-16 DK DK17158350.3T patent/DK3231801T3/en active
- 2014-05-16 RS RS20210074A patent/RS61482B1/sr unknown
- 2014-05-16 RS RS20251023A patent/RS67392B1/sr unknown
- 2014-05-16 PL PL20201593.9T patent/PL3786162T3/pl unknown
- 2014-05-16 ES ES20201593T patent/ES2960731T3/es active Active
- 2014-05-16 PT PT202015939T patent/PT3786162T/pt unknown
- 2014-05-16 MY MYPI2015002767A patent/MY174788A/en unknown
- 2014-05-16 EA EA201592199A patent/EA036448B1/ru unknown
- 2014-05-16 ES ES14732705.0T patent/ES2626793T3/es active Active
- 2014-05-16 FI FIEP20201593.9T patent/FI3786162T3/fi active
- 2014-05-16 EP EP23185889.5A patent/EP4275756B1/en active Active
- 2014-05-16 LT LTEP18215671.1T patent/LT3527263T/lt unknown
- 2014-05-16 JP JP2016514126A patent/JP6415543B2/ja active Active
- 2014-05-16 PT PT231858895T patent/PT4275756T/pt unknown
- 2014-05-16 CR CR20190156A patent/CR20190156A/es unknown
- 2014-05-16 SI SI201430239A patent/SI2997023T1/sl unknown
- 2014-05-16 TW TW103117400A patent/TWI664176B/zh active
- 2014-05-16 HR HRP20231048TT patent/HRP20231048T1/hr unknown
- 2014-05-16 KR KR1020227030853A patent/KR102663357B1/ko active Active
- 2014-05-16 SG SG11201509180WA patent/SG11201509180WA/en unknown
- 2014-05-16 US US14/279,929 patent/US9382231B2/en active Active
- 2014-05-16 MX MX2020004506A patent/MX385187B/es unknown
- 2014-05-16 EP EP18215671.1A patent/EP3527263B1/en active Active
- 2014-05-16 HR HRP20251220TT patent/HRP20251220T1/hr unknown
- 2014-05-16 EP EP20201593.9A patent/EP3786162B1/en active Active
- 2014-05-16 PE PE2020000001A patent/PE20200527A1/es unknown
- 2014-05-16 SM SM20250397T patent/SMT202500397T1/it unknown
- 2014-05-16 PL PL14732705T patent/PL2997023T3/pl unknown
- 2014-05-16 LT LTEP23185889.5T patent/LT4275756T/lt unknown
- 2014-05-16 PT PT147327050T patent/PT2997023T/pt unknown
- 2014-05-16 HU HUE20201593A patent/HUE063817T2/hu unknown
- 2014-05-16 SI SI201431754T patent/SI3527263T1/sl unknown
- 2014-05-16 PL PL23185889.5T patent/PL4275756T3/pl unknown
- 2014-05-16 HU HUE14732705A patent/HUE033587T2/hu unknown
- 2014-05-16 UA UAA201512465A patent/UA117830C2/uk unknown
- 2014-05-16 PT PT182156711T patent/PT3527263T/pt unknown
- 2014-05-16 AR ARP140101971A patent/AR096330A1/es active IP Right Grant
- 2014-05-16 TW TW110101630A patent/TWI840646B/zh active
- 2014-05-16 WO PCT/US2014/038388 patent/WO2014186706A1/en not_active Ceased
- 2014-05-16 DK DK20201593.9T patent/DK3786162T3/da active
- 2014-05-16 TR TR2019/05814T patent/TR201905814T4/tr unknown
- 2014-05-16 SM SM20170258T patent/SMT201700258T1/it unknown
- 2014-05-16 HU HUE17158350A patent/HUE043573T2/hu unknown
- 2014-05-16 KR KR1020217030190A patent/KR102442747B1/ko active Active
- 2014-05-16 SG SG10201709469SA patent/SG10201709469SA/en unknown
- 2014-05-16 ME MEP-2019-79A patent/ME03355B/me unknown
- 2014-05-16 PL PL17158350T patent/PL3231801T3/pl unknown
- 2014-05-16 CN CN201711000293.3A patent/CN107698569B/zh active Active
- 2014-05-16 EP EP14732705.0A patent/EP2997023B9/en active Active
- 2014-05-16 KR KR1020157035750A patent/KR102341908B1/ko active Active
- 2014-05-16 ES ES23185889T patent/ES3047826T3/es active Active
- 2014-05-16 HU HUE18215671A patent/HUE053122T2/hu unknown
- 2014-05-16 SI SI201431118T patent/SI3231801T1/sl unknown
- 2014-05-16 KR KR1020247014111A patent/KR102729910B1/ko active Active
- 2014-05-16 ES ES18215671T patent/ES2845210T3/es active Active
- 2014-05-16 FI FIEP23185889.5T patent/FI4275756T3/fi active
- 2014-05-16 HU HUE23185889A patent/HUE073609T2/hu unknown
- 2014-05-16 BR BR112015028501A patent/BR112015028501B8/pt active IP Right Grant
- 2014-05-16 EP EP17158350.3A patent/EP3231801B1/en active Active
- 2014-05-16 SI SI201432046T patent/SI3786162T1/sl unknown
- 2014-05-16 EA EA202090291A patent/EA039660B1/ru unknown
- 2014-05-16 LT LTEP14732705.0T patent/LT2997023T/lt unknown
- 2014-05-16 RS RS20170526A patent/RS56012B1/sr unknown
- 2014-05-16 EP EP25180368.0A patent/EP4620528A3/en active Pending
- 2014-05-16 SM SM20210040T patent/SMT202100040T1/it unknown
- 2014-05-16 TW TW108103947A patent/TWI719401B/zh active
- 2014-05-16 AU AU2014265279A patent/AU2014265279B2/en active Active
- 2014-05-16 LT LTEP17158350.3T patent/LT3231801T/lt unknown
- 2014-05-16 DK DK23185889.5T patent/DK4275756T3/da active
- 2014-05-16 SI SI201432117T patent/SI4275756T1/sl unknown
- 2014-05-16 PE PE2015002406A patent/PE20160126A1/es unknown
- 2014-05-16 ME MEP-2017-116A patent/ME02763B/me unknown
- 2014-05-16 CN CN201480032106.8A patent/CN105452239B/zh active Active
- 2014-05-16 SM SM20230352T patent/SMT202300352T1/it unknown
- 2014-05-16 CA CA2911536A patent/CA2911536C/en active Active
- 2014-05-16 PT PT17158350T patent/PT3231801T/pt unknown
- 2014-05-16 TW TW112149597A patent/TWI885650B/zh active
- 2014-05-16 PL PL18215671T patent/PL3527263T3/pl unknown
-
2015
- 2015-11-04 IL IL24245315A patent/IL242453B/en active IP Right Grant
- 2015-11-12 PH PH12015502563A patent/PH12015502563B1/en unknown
- 2015-11-13 CL CL2015003355A patent/CL2015003355A1/es unknown
- 2015-12-03 CR CR20150633A patent/CR20150633A/es unknown
-
2016
- 2016-06-20 US US15/187,296 patent/US9926301B2/en active Active
-
2017
- 2017-06-08 CY CY20171100610T patent/CY1119105T1/el unknown
-
2018
- 2018-02-15 US US15/897,598 patent/US10435392B2/en active Active
- 2018-04-18 HK HK18105021.2A patent/HK1245769B/en unknown
- 2018-08-31 AU AU2018223058A patent/AU2018223058B2/en active Active
- 2018-10-02 JP JP2018187613A patent/JP6775560B2/ja active Active
- 2018-10-02 PH PH12018502125A patent/PH12018502125A1/en unknown
-
2019
- 2019-01-22 IL IL264409A patent/IL264409B/en active IP Right Grant
- 2019-04-16 HR HRP20190713TT patent/HRP20190713T1/hr unknown
- 2019-05-10 CY CY20191100510T patent/CY1121763T1/el unknown
- 2019-08-29 US US16/555,620 patent/US11001571B2/en active Active
-
2020
- 2020-02-17 AR ARP200100433A patent/AR118120A2/es unknown
- 2020-03-19 AU AU2020202000A patent/AU2020202000B2/en active Active
- 2020-10-06 JP JP2020168950A patent/JP7126741B2/ja active Active
-
2021
- 2021-01-22 CY CY20211100050T patent/CY1123756T1/el unknown
- 2021-01-22 HR HRP20210119TT patent/HRP20210119T1/hr unknown
- 2021-04-13 US US17/229,397 patent/US11591318B2/en active Active
- 2021-04-26 IL IL282644A patent/IL282644B/en unknown
- 2021-04-29 AU AU2021202685A patent/AU2021202685B2/en active Active
- 2021-10-17 IL IL287313A patent/IL287313B/en unknown
-
2022
- 2022-08-10 JP JP2022128042A patent/JP2022163162A/ja active Pending
- 2022-10-31 AU AU2022263454A patent/AU2022263454B2/en active Active
-
2023
- 2023-01-24 US US18/101,014 patent/US11905275B2/en active Active
-
2024
- 2024-01-02 US US18/402,493 patent/US12247020B2/en active Active
- 2024-05-15 JP JP2024079435A patent/JP2024105557A/ja active Pending
-
2025
- 2025-02-05 US US19/045,868 patent/US20250206726A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519147A5 (https=) | ||
| JP2014520146A5 (https=) | ||
| US10676479B2 (en) | Imidazolepyridine compounds and uses thereof | |
| KR102534028B1 (ko) | 트리아졸로피리미딘 화합물 및 그의 용도 | |
| JP2021502387A5 (https=) | ||
| JP2015537017A5 (https=) | ||
| RU2014110623A (ru) | Пирролопиразиновые ингибиторы киназы | |
| ME02763B (me) | Derivati bipirazola kao inhibitori jak | |
| JP2019512505A5 (https=) | ||
| JP2015514056A5 (https=) | ||
| JP2018515438A5 (https=) | ||
| ES2639402T3 (es) | 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol | |
| TR201902525T4 (tr) | Janus ile alakalı kinazların (jak) inhibitörleri olarak bir veya daha fazla ilave ajan ile pirolo [2,3-d]pirimidin türevlerinin kombinasyonu. | |
| RU2007120518A (ru) | ПИРАЗОЛО [1,5,-a] ПИРИМИДИНЫ, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОИЕИНКИНАЗ | |
| JP2014513704A5 (https=) | ||
| JP2015509975A5 (https=) | ||
| RU2012148246A (ru) | 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ | |
| JP2017524022A (ja) | Ｊａｋ阻害剤としてのアミノピリミジニル化合物 | |
| HRP20171248T1 (hr) | Amino-supstituirani imidazopiridazini | |
| CA2891644A1 (en) | Aminoimidazopyridazines | |
| JP6001049B2 (ja) | Ｍｐｓ−１キナーゼ阻害剤としての置換ベンズイミダゾール類 | |
| TW201305170A (zh) | 用於治療過度增生病症及與血管生成有關之疾病之胺醇取代之２，３－二氫咪唑并［１，２－ｃ］喹唑啉衍生物 | |
| US11529350B2 (en) | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | |
| AU2018350980A1 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors | |
| CN109843883A (zh) | 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途 |